8th isap symposium
DESCRIPTION
8th ISAP Symposium. Can PK/PD be used in everyday clinical practice?. Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University of Milan, Milan, Italy. PK/PD results and evolution. }. }. Improvement of dose and intervals. Outcome resistance. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/1.jpg)
8th ISAP Symposium
Can PK/PD be used in everyday clinical practice?
Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University of Milan, Milan, Italy
![Page 2: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/2.jpg)
PK/PD results and evolution
2000
Persistend effect
Time/Conc. dependent activity
}Improvement of dose and intervals
}Outcome
resistance
?
![Page 3: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/3.jpg)
Several objectives
Phase 2-3 clinical trial
resistanceImprovement of therapy
![Page 4: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/4.jpg)
PK/PD evolution
Custom-made therapy
2000
![Page 5: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/5.jpg)
Effect overEffect over the time;the time;
Peculiar EffectsPeculiar Effects
Effect overEffect over the time;the time;
Peculiar EffectsPeculiar Effects
AADDMMEE
AADDMMEE
In VitroIn Vitroand in vivoand in vivo
activityactivity
In VitroIn Vitroand in vivoand in vivo
activityactivity
Pharmacology : what for physician?
0
2
4
6
810
12
1416
18
20
0 1 2 3 4 5 6 7 8 9 10 11 12time h
conc
entr
atio
n (µ
g/m
l)
![Page 6: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/6.jpg)
Optimizing antimicrobial therapy
Concentration at infection
site
PathogenMIC
DRUGPK
Pharmacodynamics = relationship between
concentration and effect
Bacterialkill
![Page 7: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/7.jpg)
PHARMACODYNAMICS
PEAK/ MIC
MIC
T>MICt
AUC/MIC
c
![Page 8: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/8.jpg)
Improving the probability of positive outcomes
IMPROVING THE ODDS
HOST
BUG
DRUG
![Page 9: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/9.jpg)
PK/PD parameters determining efficacy AbsorptionAbsorption Serum levelsSerum levels Distribution and penetration to site of Distribution and penetration to site of
infectioninfection Intracellular penetrationIntracellular penetration Relationship of PK parameters to MICRelationship of PK parameters to MIC
![Page 10: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/10.jpg)
Peak level of tobramycin 3mg/kg in ten patients in ICU
0.0
2.5
5.0
7.5
10.0
mg
/L
![Page 11: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/11.jpg)
Trauma
FACTORS INVOLVED IN INLAMMATION
Complement
Necrosis
Bacteria
PMNMN
Lymphocytes
TNF- IL - 1IL - 6
PAFPGELTCTXA
Protease
oxygen Radicals
endothelialDamage
Increase of capillary
permeability
Oedema
![Page 12: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/12.jpg)
VARIATIONS OF INTERSTITIAL FLUID DURING INFECTIONS
bloodINTERSTITIAL
FLUID
Cells
![Page 13: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/13.jpg)
THEORETICAL CONCENTRATION OF AN ANTIBIOTIC
Time
Serum
Interstitial fluid
Con
cent
ratio
n Large volume compartment
![Page 14: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/14.jpg)
‘‘Time above MIC’Time above MIC’
Co
nce
ntr
atio
nC
on
cen
trat
ion
M ICM IC11
TimeTime
M ICM IC22
Time Over MICPeak/MIC
![Page 15: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/15.jpg)
Ideal approach to adjust the doseInitial dosing regimen(chosen by patient’s physician)
Blood sampling( two or more post-distributional sample)
Pharmacokinetic analysis (peak,AUC,CL)
Adjust dose or/and intervals (PK/PD)
Redetermine concentrations
Adjust again ?
![Page 16: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/16.jpg)
First problemPK approach to adjust the dose is poor applicable for routinely use (at moment)
N°samples Personnel Costs
![Page 17: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/17.jpg)
second problemPK/PD breakpoints
betalactams (ceftriaxone)
aminoglycosides
quinolones
glycopeptides
macrolides
tetracyclines
![Page 18: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/18.jpg)
Program to customize the therapyin our hospital
Isolation of the pathogen and MIC
Design therapy traditionally(by patient’s physician)
Pharmacokinetics
Adjust dose or interval using PK/PD
Redetermine concentrations
![Page 19: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/19.jpg)
PK/PD values adopted
•Aminoglycosides Peak/MIC 8•Quinolones peak/MIC 10 •Betalactams peak/MIC 4
and T>MIC 70%
same value for monotherapy or combination
![Page 20: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/20.jpg)
Sampling time
•Aminoglycosides Peak : 0.5 h from end 30 min infusion•Quinolones peak : 0.5 h from end 60 min infusion•Betalactams peak :0.5 h from end 30 min infusionAnd T>MIC : 5.6 hours from start infusion
![Page 21: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/21.jpg)
Concentrations of ceftazidime and cefotaxime in serum
05
101520253035404550556065
mg
/L
C 0.5 h C 5.6 h
![Page 22: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/22.jpg)
Peak levels of amikacin
0
10
20
30
40
mg
/L
![Page 23: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/23.jpg)
PK/PD dose adjustment
Levofloxacin 500 mg to 750 OD or BID
Ciprofloxacin 500mg to 750 BID
Cefotaxime-Ceftazidime 2g q 8 to 2g q6
Amikacin 10 mg/kg OD to 15 mg/kg OD
![Page 24: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/24.jpg)
preliminary results
October 2000 – April 2001
Patients included 680
Evaluated for PK/PD 223 (32.8%)
Dose or interval adjusted 84 (37.7%)
Adjustment failed in 6 (5 cipro -1 amikacin)
![Page 25: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/25.jpg)
diagnosis
Nosocomial pneumonia 105
Sepsis 44
upper UTI 57
Necrotizing Fascitis 8
Others 9
![Page 26: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/26.jpg)
Organisms isolated
Pseudomonas aeruginosa 87
Staphylococcus aureus 42
Enterobacter species 33
Klebsiella species 15
Escherichia coli 14
Haemophilus influenzae 11
Serratia marcescens 7
Streptococcus pneumoniae 4
Stenotrophomonas spp 4
Legionella species 2
Citrobacter species 2
Acinetobacter 1
Proteus species 1
![Page 27: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/27.jpg)
AminoglicosidesDose adjusted according to creatinine clearance
Creatinine clearance % of initial dose at mL/min 24h dosing interval:
40 92% 30 86 25 81 20 75 17 70 15 67 12 61 10 56
![Page 28: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/28.jpg)
Ceftazidime-Cefotaxime-LevofloxacinDose adjusted according to creatinine clearance
>50 mL/min: normal dose 20-50 mL/min: 1/2-3/4 normal dose <20 mL/min: 1/4-1/2 normal dose
![Page 29: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/29.jpg)
Ciprofloxacin Dose adjusted according to creatinine clearance
> 20 mL/min: normal dose <20 mL/min: 1/2 normal dose
![Page 30: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/30.jpg)
outcome
Length Length hospitalizationhospitalization
- days- days**
failurefailure mortalitymortality
PK/PD PK/PD analysedanalysed
11 (7-16)11 (7-16) 39/223 39/223 (17.5%)(17.5%)
11 11
(4.9%)(4.9%)
PK/PDPK/PD
Not Not analysedanalysed
16 (9-23 )16 (9-23 ) 147/457147/457
(31.9 %)(31.9 %)
4646
(10.1%)(10.1%)
*From the diagnosis of infection
![Page 31: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/31.jpg)
0 25 50 75 100 125 150 1750
5
10
15
20
hours to adjust doses
ho
spit
aliz
atio
n d
ays
correlation between time to adjust the dose and hospitalisation days
![Page 32: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/32.jpg)
Conclusions I
The PK/PD approach may:
improve the outcome
shorten the time to clinical improvement
Reduce the length of hospitalisation
![Page 33: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/33.jpg)
Conclusions II
The initial higher costs for analysis and personnel are compensated for the reduction of the hospitalisation, with a financial gain
![Page 34: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/34.jpg)
Conclusions III
Can PK/PD be used
in everyday clinical practice?
yes
![Page 35: 8th ISAP Symposium](https://reader035.vdocuments.mx/reader035/viewer/2022062408/568132c2550346895d9985c0/html5/thumbnails/35.jpg)
Conclusions IVhomework
When you came back at home, please try to convince Top Managers as well as Physicians (mainly surgeons), that the PK/PD approach is clinically and economically advantageous